Article
Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.
BMC cancer - 12 Dec 2022
Shang Kai, Huang Hongxiang, Xu Yongkang, Liu Yangyang, Lu Zhihui, Chen Li
Abstract excerpt
PURPOSE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with cytotoxic chemotherapy are highly effective in the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. The purpose of this study is to evaluate the efficacy and safety of this combination in advanced NSCLC patients with an EGFR/TP53 co-mutation. METHODS: Ninety-five advanced NSCLC patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.